Demographic -1-

		Placebo N=32	CTLA .5 N=26	CTLA 2 N=32	CTLA 10 N=32	LEA .5 N=32	LEA 2 N=29	LEA 10 N=31	Total N=214
Gender	Male	6 (19%)	4 (15%)	9 (28%)	10 (31%)	9 (28%)	9 (31%)	7 (23%)	54 (25%)
	Female	26 (81%)	22 (85%)	23 (72%)	22 (69%)	23 (72%)	20 (69%)	24 (77%)	.160 (75%)
Race	White	30 (94%)	23 (88%)	30 (94%)	30 (94%)	29 (91%)	25 (86%)	27 (87%)	194 (91%)
	Black	2 (6%)	0 (0%)	0 (0%)	1 (3%)	1 (3 %)	3 (10%)	2 (6%)	9 (4%)
	Other	0 (0%)	3 (12%)	2 (6%)	1 (3%)	2 (6%)	1 (3%)	2 (6%)	11 (5%)
Disease Duration	< 2 years	12 (38%)	5 (19%)	8 (25%)	12 (38%)	10 (31%)	10 (34%)	11 (35%)	68 (32%)
	2-5 years	14 (44%)	11 (42%)	18 (56%)	13 (41%)	14 (44%)	14 (48%)	12 (39%)	96 (45%)
	5-7 years	6 (19%)	8 (31%)	6 (19%)	6 (19%)	6 (19%)	5 (17%)	7 (23%)	44 (21%)
	> 7years	0 (0%)	2 (8%)	0 (0%)	1 (3%)	2 (6%)	0 (0%)	1 (3%)	6 (3%)
Duration Disease (years)	N	32	26	32	32	32	29	31	214
	Mean	3.2	4.2	3.3	3.4	3.7	3.1	3	3.4
	Sd	2	2	1.7	2.1	2	1.8	2.2	2
	Min	0.3	0.2	0.4	0	0.7	0.4	0	0
	Max	7	7.5	6.8	7.3	7.6	7	7.1	7.6

FIG. 1A

24 December 2004

Demographic -2-

		Placebo N=32	CTLA .5 N=26	CTLA 2 N=32	CTLA 10 N=32	LEA .5 N=32	LEA 2 N=29	LEA 10 N=31	Total N=214
Gender	Male	6 (19%)	4 (15%)	9 (28%)	10 (31%)	9 (28%)	9 (31%)	7 (23%)	54 (25%)
	Female	26 (81%)	22 (85%)	23 (72%)	22 (69%)	23 (72%)	20 (69%)	24 (77%)	160 (75%)
Age	N	32	26	32	32	32	29	31	214
	Mean	48.3	46.9	46.2	51.5	49.3	50.8	45.6	48.4
	Sd	11.7	12.2	13.4	11.5	8.8	10.7	10.1	11.3
	Min	22	25	21	24	27	24	28	21
	Max	66	64	64	66	66	65	64	66
Weight (kg)	N	32	26	32	32	32	29	31	214
	Mean	72.9	70.6	72.7	70	69.8	68.9	71.7	71
	Sd	13.5	17.4	14.4	16.7	12.8	12.1	15.8	14.6
	Min	46.7	45	50	40.1	48	47	39.2	39.2
	Max	98.2	101.3	99	101.3	95	93.8	99	101.3
Disease activity (patient)	N	32	26	32	32	32	29	31	215
	Mean	3.6	3.6	3.7	3.6	3.5	3.6	3.5	3.6
	Sd	0.9	0.9	0.9	0.9	0.8	0.8	0.7	0.8
	Min	2	2	2	2	2	2	2	2
	Max	5	5	5	5	5	5	5	5

FIG. 1B

Demographic - Disease -

		Placebo N=32	CTLA .5 N=26	CTLA 2 N=32	CTLA 10 N=32	LEA .5 N=32	LEA 2 N=29	LEA 10 N=31	Total N=214
Disease activity (physician)	N	32	26	32	32	32	29	31	214
	Mean	3.6	3.5	3.5	3.7	3.4	3.4	3.5	3.5
	Sd	0.7	0.6	0.8	1	0.6	0.8	0.6	0.7
	Min	2	3	2	2	2	2	3	2
	Max	5	5	5	5	5	5	5	5
ESR	N	32	26	32	32	32	29	30	213
	Mean	43.3	35.2	41.6	36.3	29.8	40.9	39.3	38.1
	Sd	29.4	22.5	27.4	27.9	24.2	30.2	24.6	26.8
	Min	2	4	4	3	0	6	2	0
	Max	116	90	94	98	91	110	102	116
Physical function (score)	N	32	26	31	32	32	29	31	213
	Mean	16.8	15.5	16.2	17.1	15.3	16.3	16.1	16.2
	Sd	5.4	4.2	5.5	5.7	3.7	4.8	3.8	4.8
	Min	8	8	8	8	8	8	9	8
	Max	32	23	26	28	24	26	26	32
CRP	N	30	23	31	31	31	28	31	205
	Mean	56.7	26.4	48	33.6	28.1	48.1	37.5	40.1
	Sd	62.7	30.3	47.3	46	39.1	64.5	35.2	48.6
	Min	2	5	3	3	3	3	3	2
	Max	248	115	198	182	200	333	135	333

FIG. 1C

24 December 2004

Demographic - Disease -

		Placebo N=32	CTLA .5 N=26	CTLA 2 N=32	CTLA 10 N=32	LEA .5 N=32	LEA 2 N=29	LEA 10 N=31	Total N=214
Tender joints (score)	N	32	26	32	32	32	29	31	214
	Mean	32.1	32.5	32.1	29.4	25.6	30.7	30.6	30.4
	Sd	14.8	14.8	15	14.6	12	13.3	12.9	13.9
	Min	12	14	11	12	12	12	12	11
	Max	63	64	68.	68	61	63	59	68
Swollen joints (score)	N	32	26	32	32	32	29	31	214
	Mean	23.9	18.6	26.9	22.7	18.3	22.6	19.9	21.9
	Sd	10	6.3	11.4	12.7	7.6	8.5	8.9	10
	Min	10	10	10	10	10	10	10	10
	Max	51	33	53	58	36	40	44	58
Pain (score)	N	32	26	32	32	32	29	31	214
	Mean	3.5	3.4	3.5	3.5	3.5	3.3	3.5	3.5
	Sd	0.9	0.6	0.6	1	0.7	0.8	0.7	0.8
	Min	2	2	2	1	2	2	3	1
	Max	5	5	5	5	5	5	5	5
AM stiffness (min.)	N	31	26	32	31	32	29	30	211
	Mean	156.6	211.5	145.2	149.5	160.9	160.3	147.5	160.5
	Sd	121.5	370.6	102.1	148.7	151.1	152.3	258.3	198.1
	Min	30	0	5	35	30	0	15	0
	Max	600	1440	420	720	600	720	1440	1440

FIG. 1D

Demographic- Prior treatments -

		Placebo N=32	CTLA .5 N=26	CTLA 2 N=32	CTLA 10 N=32	LEA .5 N=32	LEA 2 N=29	LEA 10 N=31	Total N=214
Etanercept	Yes	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	No	32 (100%)	26 (100%)	32 (100%)	32 (100%)	32 (100%)	29 (100%)	31 (100%)	214 (100%)
Methotrexate	Yes	23 (72%)	22 (85%)	26 (81%)	24 (75%)	24 (75%)	21 (72%)	28 (90%)	168 (79%)
	No	9 (28%)	4 (15%)	6 (19%)	8 (25%)	8 (25%)	8 (28%)	3 (10%)	46 (21%)
Other DMARDs	Yes	28 (86%)	23 (88%)	25 (78%)	26 (81%)	28 (86%)	24 (83%)	25 (81%)	179 (84%)
	No	4 (13%)	3 (12%)	7 (22%)	6 (19%)	4 (13%)	5 (17%)	6 (19%)	35 (16%)
C-Steroids	Yes	31 (97%)	26 (100%)	29 (91%)	27 (84%)	27 (84%)	28 (97%)	24 (77%)	192 (90%)
	No	1 (3%)	0 (0%)	3 (9%)	5 (16%)	5 (16%)	1 (3%)	7 (23%)	22 (10%)
NSAIDs	Yes	27 (84%)	20 (77%)	30 (94%)	29 (91%)	26 (81%)	25 (86%)	25 (77%)	181 (85%)
	No	5 (16%)	6 (23%)	2 (6%)	3 (9%)	6 (19%)	4 (14%)	7 (23%)	33 (15%)
Other	Yes	30 (94%)	22 (85%)	29 (91%)	30 (94%)	31 (97%)	29 (100%)	29 (94%)	200 (93%)
	No	2 (6%)	4 (15%)	3 (9%)	2 (6%)	1 (3%)	0 (0%)	2 (6%)	14 (7%)

FIG. 1E

24 December 2004



Summary of Discontinuations by Reason
on or before Day 85
ALL
RA Flares
Other AEs
Percent of Total Sample
60
50
40
30
20
10
0
PLACEBO
CTL .5mg/kg
CTL 2mg/kg
CTL 10mg/kg
LEA .5mg/kg
LEA 2mg/kg
LEA 10mg/kg
Treatment Groups

FIG. 2



ACR response at Day 85
ACR 20
ACR 50
ACR 70
response rate
70
60
50
40
30
20
10
0
Placebo
CTLA .5
CTLA 2
CTLA 10
LEA .5
LEA 2
LEA 10

FIG. 3A



ACR20 Response on Day 85
with 95% Confidence Limits
Response Rate
0
20
40
60
80
PLACEBO
CTL .5mg/kg
CTL 2mg/kg
CTL 10mg/kg
LEA .5mg/kg
LEA 2mg/kg
LEA 10mg/kg
Treatment Groups

FIG. 3B



Difference in ACR20 Response on Day 85 w.r.t
(95% CLs)
Response Rate
80
60
40
20
0
-20
-40
.5mg/kg 2 mg/kg 10mg/kg
CTLA
.5mg/kg 2mg/kg 10mg/kg
LEA

FIG. 3C



Basic (20%) Clinical Response in swollen & tender joint count
improvement > 20%
response < 20%
% of patients
0
10
20
30
40
50
60
70
placebo
cda 5
cda 2
cda 10
tea 5
tea 2
tea 10

FIG. 4A



Clinical Response at Day 85
change in swollen & tender joint count response in percentage
> 20%
> 50%
> 70%
=100%
% of patients
0
10
20
30
40
50
60
70
80
Placebo
ctla .5
ctla 2
ctla 10
lea .5
lea 2
lea 10

FIG. 4B



Pain
(Likert scale unit changes)
pain score changes from baseline
worse -2
worse -1
same
better 1
better 2
better 3
better 4
% of patients
50
40
30
20
10
0
-10
-20
-30
Placebo
CTLA .5
CTLA 2
CTLA 10
LEA .5
LEA 2
LEA 10

FIG. 5A



Patient Global Disease Changes
(Likert scale unit changes)
score changes from baseline
worse -2
worse -1
same
better 1
better 2
better 3
better 4
% of patients
60
50
40
30
20
10
0
-10
-20
Placebo
CTLA.5
CTLA 2
CTLA 10
LEA.5
LEA 2
LEA 10

FIG. 5B



Physician Global Disease Changes
(Likert scale unit changes)
score changes from baseline
worse -1
same
better 1
better 2
better 3
% of pat
70
60
50
40
30
20
10
0
-10
-20
Placebo
CTLA .5
CTLA 2
CTLA 10
LEA .5
LEA 2
LEA 10

FIG. 5C



Pain
- Changes from Baseline -
worse
same
better <2
better >2
% of pat
70
60
50
40
30
20
10
0
-10
-20
-30
Placebo
CTLA .5
CTLA 2
CTLA 10
LEA .5
LEA 2
LEA 10

FIG. 5D



Patient Global Assessment
- Disease Activity Change from Baseline -
worse
same
better <2
better >2
% of pat.
70
60
50
40
30
20
10
0
-10
-20
-30
Placebo
CTLA .5
CTLA 2
CTLA 10
LEA .5
LEA 2
LEA 10

FIG 6A



Physician Global Assessment
-Disease Activity Changes from Baseline -
worse
same
better <2
better >2
% of pat.
100
80
60
40
20
0
-20
Placebo
CTLA.5
CTLA 2
CTLA 10
LEA.5
LEA 2
LEA 10

FIG. 6B



Percent Reduction in CRP Levels on Day 85 compared to Baseline
50
25
0
-25
-50
% Reductio
PLACEBO
CTL .5mg/kg
CTL 2mg/kg
CTL 10mg/kg
LEA .5mg/kg
LEA 2mg/kg
LEA 10mg/kg
Treatment Groups

FIG. 7A



Difference in CRP Reduction w.r.t Combined Placebo groups (95% CLs) on Day 85
% Reduction difference
60
40
20
0
-20
-40
-60
-80
-100
-120
.5mg/kg 2 mg/kg 10mg/kg
CTLA
.5mg/kg 2mg/kg 10mg/kg
LEA

FIG. 7B



CRP
mean change from baseline
CRP
mg/dl
10
5
0
-5
-10
-15
-20
-25
placebo
ctla .5
ctla 2
ctla 10
lea .5
lea 2
lea 10

FIG. 7C



IL-2r
mean change from baseline
IL-2r
pcg/ml
0
-100
-200
-300
-400
-500
-600
-700
placebo
ctla .5
ctla 2
ctla 10
lea .5
lea 2
lea 10

FIG. 8



CTLA tender joints
- median difference from baseline -
Placebo
ctla .5
ctla 2
ctla 10
median change from baseline
16
14
12
10
8
6
4
2
0
-2
-4
D15
D29
D43
D57
D71
D85
visit days

FIG. 9A



CTLA tender joints
- mean difference from baseline -
Placebo
ctla .5
ctla 2
ctla 10
mean changes from baseline
0
2
4
6
8
10
12
14
16
D15
D29
D43
D57
D71
D85
visit days

FIG. 9B



CTLA swollen joints
- median difference from baseline -
Placebo
ctla .5
ctla 2
ctla 10
median changes from baseline
0
2
4
6
8
10
12
D15
D29
D43
D57
D71
D85
visit days

FIG. 10A



CTLA swollen joints
- mean difference from baseline -
Placebo
ctla .5
ctla 2
ctla 10
mean changes from baseline
12
10
8
6
4
2
0
D15
D29
D43
D57
D71
D85
visit days

FIG. 10B



CTLA Pain Assessment
- mean difference from baseline -
Placebo
ctla .5
ctla 2
ctla 10
mean changes from baseline
1.2
1
0.8
0.6
0.4
0.2
0
D15
D29
D43
D57
D71
D85
visit days

FIG. 11

CTLA
Patient Assessment Disease Activity
- mean difference from baseline -




FIG. 12A

CTLA

Physician Assessment Disease Activity

- mean difference from baseline -




FIG. 12B



LEA tender joints
- median difference from baseline -
Placebo
lea .5
lea 2
lea 10
median changes
16
14
12
10
8
6
4
2
0
-2
-4
D15
D29
D43
D57
D71
D85
visit days

FIG. 13A



LEA tender joints
- mean change from baseline -
Placebo
lea .5
lea 2
lea 10
mean changes from baseline
0
2
4
6
8
10
12
14
16
18
D15
D29
D43
D57
D71
D85
visit days

FIG. 13B



LEA swollen joints
- median difference from baseline -
Placebo
lea .5
lea 2
lea 10
median changes from baseline
14
12
10
8
6
4
2
0
D15
D29
D43
D57
D71
D85
visit days

FIG. 14A



LEA swollen joints
- mean change from baseline -
Placebo
lea .5
lea 2
lea 10
mean changes from baseline
0
2
4
6
8
10
12
14
D15
D29
D43
D57
D71
D85
visit days

FIG. 14B



LEA Pain Assessment
- mean change from baseline -
Placebo
lea .5
lea 2
lea 10
mean changes from baseline
1.2
1
0.8
0.6
0.4
0.2
0
D15
D29
D43
D57
D71
D85
visit days

FIG. 15

LEA

Patient Assessment Disease Activity

- mean difference from baseline -




FIG. 16A

LEA

Physician Assessment Disease Activity

- mean difference from baseline -




FIG. 16B

24 December 2004

Percent Improvement in HAQ Levels on Day 85 compared to Baseline




FIG. 17

```
ATGGGTGTACTGCTCACACAGAGGACGCTGCTCAGTCTGGTCCTTGCACTCCTGTTTCCA      -19
M~~G~~V~~L~~L~~T~~Q~~R~~T~~L~~L~~S~~L~~V~~L~~A~~L~~L~~F~~P~~      -7

AGCATGGCGAGCATGGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGA      +42
S~~M~~A~~S~~M~~A~~M~~H~~V~~A~~Q~~P~~A~~V~~V~~L~~A~~S~~S~~R~~      +14
                  +1

GGCATCGCTAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTG      +102
G~~I~~A~~S~~F~~V~~C~~E~~Y~~A~~S~~P~~G~~K~~A~~T~~E~~V~~R~~V~~      +34

ACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATG      +162
T~~V~~L~~R~~Q~~A~~D~~S~~Q~~V~~T~~E~~V~~C~~A~~A~~T~~Y~~M~~M~~      +54

GGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAA      +222
G~~N~~E~~L~~T~~F~~L~~D~~D~~S~~I~~C~~T~~G~~T~~S~~S~~G~~N~~Q~~      +74

GTGAACCTCACTATCCAAGGACTGAGGGCCATGGACACGGGACTCTACATCTGCAAGGTG      +282
V~~N~~L~~T~~I~~Q~~G~~L~~R~~A~~M~~D~~T~~G~~L~~Y~~I~~C~~K~~V~~      +94

GAGCTCATGTACCCACCGCCATACTACGAGGGCATAGGCAACGGAACCCAGATTTATGTA      +342
E~~L~~M~~Y~~P~~P~~P~~Y~~Y~~E~~G~~I~~G~~N~~G~~T~~Q~~I~~Y~~V~~      +114

ATTGATCCAGAACCGTGCCCAGATTCTGATCAGGAGCCCAAATCTTCTGACAAAACTCAC      +402
I~~D~~P~~E~~P~~C~~P~~D~~S~~D~~Q~~E~~P~~K~~S~~S~~D~~K~~T~~H~~      +134

ACATCCCCACCGTCCCCAGCACCTGAACTCCTGGGGGGGATCGTCAGTCTTCCTCTTCCCC      +462
T~~S~~P~~P~~S~~P~~A~~P~~E~~L~~L~~G~~G~~S~~S~~V~~F~~L~~F~~P~~      +154

CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG      +522
P~~K~~P~~K~~D~~T~~L~~M~~I~~S~~R~~T~~P~~E~~V~~T~~C~~V~~V~~V~~      +174

GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG      +582
D~~V~~S~~H~~E~~D~~P~~E~~V~~K~~F~~N~~W~~Y~~V~~D~~G~~V~~E~~V~~      +194

CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC      +642
H~~N~~A~~K~~T~~K~~P~~R~~E~~E~~Q~~Y~~N~~S~~T~~Y~~R~~V~~V~~S~~      +214

GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC      +702
V~~L~~T~~V~~L~~H~~Q~~D~~W~~L~~N~~G~~K~~E~~Y~~K~~C~~K~~V~~S~~      +234

AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA      +762
N~~K~~A~~L~~P~~A~~P~~I~~E~~K~~T~~I~~S~~K~~A~~K~~G~~Q~~P~~R~~      +254

GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGC      +822
E~~P~~Q~~V~~Y~~T~~L~~P~~P~~S~~R~~D~~E~~L~~T~~K~~N~~Q~~V~~S~~      +274

CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT      +882
L~~T~~C~~L~~V~~K~~G~~F~~Y~~P~~S~~D~~I~~A~~V~~E~~W~~E~~S~~N~~      +294

GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC      +942
G~~Q~~P~~E~~N~~N~~Y~~K~~T~~T~~P~~P~~V~~L~~D~~S~~D~~G~~S~~F~~      +314

TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCA      +1002
F~~L~~Y~~S~~K~~L~~T~~V~~D~~K~~S~~R~~W~~Q~~Q~~G~~N~~V~~F~~S~~      +334

TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT      +1062
C~~S~~V~~M~~H~~E~~A~~L~~H~~N~~H~~Y~~T~~Q~~K~~S~~L~~S~~L~~S~~      +354

CCGGGTAAATGA
P~~G~~K~~*
```

FIG. 18

```
ATGGGTGTACTGCTCACACAGAGGACGCTGCTCAGTCTGGTCCTTGCACTCCTGTTTCCA      -19
M~~G~~V~~L~~L~~T~~Q~~R~~T~~L~~L~~S~~L~~V~~L~~A~~L~~L~~F~~P~~      -7

AGCATGGCGAGCATGGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGA      +42
S~~M~~A~~S~~M~~A~~M~~H~~V~~A~~Q~~P~~A~~V~~V~~L~~A~~S~~S~~R~~      +14
                  +1

GGCATCGCTAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAATATACTGAGGTCCGGGTG      +102
G~~I~~A~~S~~F~~V~~C~~E~~Y~~A~~S~~P~~G~~K~~Y~~T~~E~~V~~R~~V~~      +34

ACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATG      +162
T~~V~~L~~R~~Q~~A~~D~~S~~Q~~V~~T~~E~~V~~C~~A~~A~~T~~Y~~M~~M~~      +54

GGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAA      +222
G~~N~~E~~L~~T~~F~~L~~D~~D~~S~~I~~C~~T~~G~~T~~S~~S~~G~~N~~Q~~      +74

GTGAACCTCACTATCCAAGGACTGAGGGCCATGGACACGGGACTCTACATCTGCAAGGTG      +282
V~~N~~L~~T~~I~~Q~~G~~L~~R~~A~~M~~D~~T~~G~~L~~Y~~I~~C~~K~~V~~      +94

GAGCTCATGTACCCACCGCCATACTACGAGGGCATAGGCAACGGAACCCAGATTTATGTA      +342
E~~L~~M~~Y~~P~~P~~P~~Y~~Y~~E~~G~~I~~G~~N~~G~~T~~Q~~I~~Y~~V~~      +114

ATTGATCCAGAACCGTGCCCAGATTCTGATCAGGAGCCCAAATCTTCTGACAAAACTCAC      +402
I~~D~~P~~E~~P~~C~~P~~D~~S~~D~~Q~~E~~P~~K~~S~~S~~D~~K~~T~~H~~      +134

ACATCCCCACCGTCCCCAGCACCTGAACTCCTGGGGGGGATCGTCAGTCTTCCTCTTCCCC      +462
T~~S~~P~~P~~S~~P~~A~~P~~E~~L~~L~~G~~G~~S~~S~~V~~F~~L~~F~~P~~      +154

CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG      +522
P~~K~~P~~K~~D~~T~~L~~M~~I~~S~~R~~T~~P~~E~~V~~T~~C~~V~~V~~V~~      +174

GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG      +582
D~~V~~S~~H~~E~~D~~P~~E~~V~~K~~F~~N~~W~~Y~~V~~D~~G~~V~~E~~V~~      +194

CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC      +642
H~~N~~A~~K~~T~~K~~P~~R~~E~~E~~Q~~Y~~N~~S~~T~~Y~~R~~V~~V~~S~~      +214

GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC      +702
V~~L~~T~~V~~L~~H~~Q~~D~~W~~L~~N~~G~~K~~E~~Y~~K~~C~~K~~V~~S~~      +234

AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA      +762
N~~K~~A~~L~~P~~A~~P~~I~~E~~K~~T~~I~~S~~K~~A~~K~~G~~Q~~P~~R~~      +254

GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGC      +822
E~~P~~Q~~V~~Y~~T~~L~~P~~P~~S~~R~~D~~E~~L~~T~~K~~N~~Q~~V~~S~~      +274

CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT      +882
L~~T~~C~~L~~V~~K~~G~~F~~Y~~P~~S~~D~~I~~A~~V~~E~~W~~E~~S~~N~~      +294

GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC      +942
G~~Q~~P~~E~~N~~N~~Y~~K~~T~~T~~P~~P~~V~~L~~D~~S~~D~~G~~S~~F~~      +314

TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCA      +1002
F~~L~~Y~~S~~K~~L~~T~~V~~D~~K~~S~~R~~W~~Q~~Q~~G~~N~~V~~F~~S~~      +334

TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT      +1062
C~~S~~V~~M~~H~~E~~A~~L~~H~~N~~H~~Y~~T~~Q~~K~~S~~L~~S~~L~~S~~      +354

CCGGGTAAATGA
P~~G~~K~~*
```

FIG. 19

```
ATGGGTGTACTGCTCACACAGAGGACGCTGCTCAGTCTGGTCCTTGCACTCCTGTTTCCA
M--G--V--L--L--T--Q--R--T--L--L--S--L--V--L--A--L--L--F--P--

AGCATGGCGAGCATGGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGA
S--M--A--S--M--A--M--H--V--A--Q--P--A--V--V--L--A--S--S--R--

GGCATCGCTAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAATTGACTGAGGTCCGGGTG
G--I--A--S--F--V--C--E--Y--A--S--P--G--K--L--T--E--V--R--V--

ACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATG
T--V--L--R--Q--A--D--S--Q--V--T--E--V--C--A--A--T--Y--M--M--

GGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAA
G--N--E--L--T--F--L--D--D--S--I--C--T--G--T--S--S--G--N--Q--

GTGAACCTCACTATCCAAGGACTGAGGGCCATGGACACGGGACTCTACATCTGCAAGGTG
V--N--L--T--I--Q--G--L--R--A--M--D--T--G--L--Y--I--C--K--V--

GAGCTCATGTACCCACCGCCATACTACGAGGGCATAGGCAACGGAACCCAGATTTATGTA
E--L--M--Y--P--P--P--Y--Y--E--G--I--G--N--G--T--Q--I--Y--V--

ATTGATCCAGAACCGTGCCCAGATTCTGATCAGGAGCCCAAATCTTCTGACAAAACTCAC
I--D--P--E--P--C--P--D--S--D--Q--E--P--K--S--S--D--K--T--H--

ACATCCCCACCGTCCCCAGCACCTGAACTCCTGGGGGGATCGTCAGTCTTCCTCTTCCCC
T--S--P--P--S--P--A--P--E--L--L--G--G--S--S--V--F--L--F--P--

CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG
P--K--P--K--D--T--L--M--I--S--R--T--P--E--V--T--C--V--V--V--

GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
D--V--S--H--E--D--P--E--V--K--F--N--W--Y--V--D--G--V--E--V--

CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
H--N--A--K--T--K--P--R--E--E--Q--Y--N--S--T--Y--R--V--V--S--

GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC
V--L--T--V--L--H--Q--D--W--L--N--G--K--E--Y--K--C--K--V--S--

AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA
N--K--A--L--P--A--P--I--E--K--T--I--S--K--A--K--G--Q--P--R--

GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGC
E--P--Q--V--Y--T--L--P--P--S--R--D--E--L--T--K--N--Q--V--S--

CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
L--T--C--L--V--K--G--F--Y--P--S--D--I--A--V--E--W--E--S--N--

GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC
G--Q--P--E--N--N--Y--K--T--T--P--P--V--L--D--S--D--G--S--F--

TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCA
F--L--Y--S--K--L--T--V--D--K--S--R--W--Q--Q--G--N--V--F--S--

TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
C--S--V--M--H--E--A--L--H--N--H--Y--T--Q--K--S--L--S--L--S--

CCGGGTAAATGA----------
P--G--K--*----------
```

FIG. 20

```
ATGGGTGTACTGCTCACACAGAGGACGCTGCTCAGTCTGGTCCTTGCACTCCTGTTTCCA
M  G  V  L  L  T  Q  R  T  L  L  S  L  V  L  A  L  L  F  P

AGCATGGCGAGCATGGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGA
S  M  A  S  M  A  M  H  V  A  Q  P  A  V  V  L  A  S  S  R

GGCATCGCTAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAACTACTGAGGTCCGGGTG
G  I  A  S  F  V  C  E  Y  A  S  P  G  K  T  T  E  V  R  V

ACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATG
T  V  L  R  Q  A  D  S  Q  V  T  E  V  C  A  A  T  Y  M  M

GGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAA
G  N  E  L  T  F  L  D  D  S  I  C  T  G  T  S  S  G  N  Q

GTGAACCTCACTATCCAAGGACTGAGGGCCATGGACACGGGACTCTACATCTGCAAGGTG
V  N  L  T  I  Q  G  L  R  A  M  D  T  G  L  Y  I  C  K  V

GAGCTCATGTACCCACCGCCATACTACGAGGGCATAGGCAACGGAACCCAGATTTATGTA
E  L  M  Y  P  P  Y  Y  E  G  I  G  N  G  T  Q  I  Y  V

ATTGATCCAGAACCGTGCCCAGATTCTGATCAGGAGCCCAAATCTTCTGACAAAACTCAC
I  D  P  E  P  C  P  D  S  D  Q  E  P  K  S  S  D  K  T  H

ACATCCCCACCGTCCCCAGCACCTGAACTCCTGGGGGGATCGTCAGTCTTCCTCTTCCCC
T  S  P  P  S  P  A  P  E  L  L  G  G  S  S  V  F  L  F  P

CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG
P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V

GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
D  V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V

CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
H  N  A  K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S

GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC
V  L  T  V  L  H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S

AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA
N  K  A  L  P  A  P  I  E  K  T  I  S  K  A  K  G  Q  P  R

GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGC
E  P  Q  V  Y  T  L  P  P  S  R  D  E  L  T  K  N  Q  V  S

CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
L  T  C  L  V  K  G  F  Y  P  S  D  I  A  V  E  W  E  S  N

GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC
G  Q  P  E  N  N  Y  K  T  T  P  P  V  L  D  S  D  G  S  F

TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCA
F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  G  N  V  F  S

TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  S  L  S

CCGGGTAAATGA**********
P  G  K  *
```

FIG. 21

```
ATGGGTGTACTGCTCACACAGAGGACGCTGCTCAGTCTGGTCCTTGCACTCCTGTTTCCA
M--G--V--L--L--T--Q--R--T--L--L--S--L--V--L--A--L--L--F--P--

AGCATGGCGAGCATGGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGA
S--M--A--S--M--A--N--H--V--A--Q--P--A--V--V--L--A--S--S--R--

GGCATCGCTAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAATGGACTGAGGTCCGGGTG
G--I--A--S--F--V--C--E--Y--A--S--P--G--K--W--T--E--V--R--V--

ACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATG
T--V--L--R--Q--A--D--S--Q--V--T--E--V--C--A--A--T--Y--M--M--

GGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAA
G--N--E--L--T--F--L--D--D--S--I--C--T--G--T--S--S--Q--N--Q--

GTGAACCTCACTATCCAAGGACTGAGGGCCATGGACACGGGACTCTACATCTGCAAGGTG
V--N--L--T--I--Q--G--L--R--A--M--D--T--G--L--Y--I--C--K--V--

GAGCTCATGTACCCACCGCCATACTACGAGGGCATAGGCAACGGAACCCAGATTTATGTA
E--L--M--Y--P--P--P--Y--Y--E--G--I--G--N--G--T--Q--I--Y--V--

ATTGATCCAGAACCGTGCCCAGATTCTGATCAGGAGCCCAAATCTTCTGACAAAACTCAC
I--D--P--E--P--C--P--D--S--D--Q--E--P--K--S--S--D--K--T--H--

ACATCCCCACCGTCCCCAGCACCTGAACTCCTGGGGGGATCGTCAGTCTTCCTCTTCCCC
T--S--P--P--S--P--A--P--E--L--L--G--G--S--S--V--F--L--F--P--

CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG
P--K--P--K--D--T--L--M--I--S--R--T--P--E--V--T--C--V--V--V--

GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
D--V--S--H--E--D--P--E--V--K--F--N--W--Y--V--D--G--V--E--V--

CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
H--N--A--K--T--K--P--R--E--E--Q--Y--N--S--T--Y--R--V--V--S--

GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC
V--L--T--V--L--H--Q--D--W--L--N--G--K--E--Y--K--C--K--V--S--

AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA
N--K--A--L--P--A--P--I--E--K--T--I--S--K--A--K--G--Q--P--R--

GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGC
E--P--Q--V--Y--T--L--P--P--S--R--D--E--L--T--K--N--Q--V--S--

CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
L--T--C--L--V--K--G--F--Y--P--S--D--I--A--V--E--W--E--S--N--

GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC
G--Q--P--E--N--N--Y--K--T--T--P--P--V--L--D--S--D--G--S--F--

TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCA
F--L--Y--S--K--L--T--V--D--K--S--R--W--Q--Q--G--N--V--F--S--

TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
C--S--V--M--H--E--A--L--H--N--H--Y--T--Q--K--S--L--S--L--S--

CCGGGTAAATGA**********
P--G--K--*----------
```

FIG. 22

ONCOSTATIN M SIGNAL PEPTIDE

```
M   G   V   L   L   T   Q   R   T   L   L   S   L   V   L
ATG GGT GTA CTG CTC ACA CAG AGG ACG CTG CTC AGT CTG GTC CTT   45

                                    -1  +1
A   L   L   F   P   S   M   A   S   M   A   M   H   V   A
GCA CTC CTG TTT CCA AGC ATG GCG AGC ATG GCA ATG CAC GTG GCC   90

Q   P   A   V   V   L   A   S   S   R   G   I   A   S   F
CAG CCT GCT GTG GTA CTG GCC AGC AGC CGA GGC ATC GCC AGC TTT   135

V   C   E   Y   A   S   P   G   K   A   T   E   V   R   V
GTG TGT GAG TAT GCA TCT CCA GGC AAA GCC ACT GAG GTC CGG GTG   180

T   V   L   R   Q   A   D   S   Q   V   T   E   V   C   A
ACA GTG CTT CGG CAG GCT GAC AGC CAG GTG ACT GAA GTC TGT GCG   225

A   T   Y   M   M   G   N   E   L   T   F   L   D   D   S
GCA ACC TAC ATG ATG GGG AAT GAG TTG ACC TTC CTA GAT GAT TCC   270

I   C   T   G   T   S   S   G   N   Q   V   N   L   T   I
ATC TGC ACG GGC ACC TCC AGT GGA AAT CAA GTG AAC CTC ACT ATC   315

Q   G   L   R   A   M   D   T   G   L   Y   I   C   K   V
CAA GCA CTG AGG GCC ATG GAC ACG GGA CTC TAC ATC TGC AAG GTG   360

                                                GLYCOSYLATION SITE

E   L   M   Y   P   P   P   Y   Y   L   G   I   G   N   G
GAG CTC ATG TAC CCA CCG CCA TAC TAC CTG GGC ATA GGC AAC GGA   405

T   Q   I   Y   V   I   D   P   E   P   C   P   D   S   D
ACC CAG ATT TAT GTA ATT GAT CCA GAA CCG TGC CCA GAT TCT GAC   450

F   L   L   W   I   L   A   A   V   S   S   G   L   F   F
TTC CTC CTC TGG ATC CTT GCA GCA GTT AGT TCG GGG TTG TTT TTT   495

Y   S   F   L   L   T   A   V   S   L   S   K   M   L   K
TAT AGC TTT CTC CTC ACA GCT GTT TCT TTG AGC AAA ATG CTA AAG   540

K   R   S   P   L   T   T   G   V   Y   V   K   M   P   P
AAA AGA AGC CCT CTT ACA ACA GGG GTC TAT GTG AAA ATG CCC CCA   585

T   E   P   E   C   E   K   Q   F   Q   P   Y   F   I   P
ACA GAG CCA GAA TGT GAA AAG CAA TTT CAG CCT TAT TTT ATT CCC   630

I   N
ATC AAT                                                     636
```

FIG. 23

```
ATGGGTGTACTGCTCACACAGAGGACGCTGCTCAGTCTGGTCCTTGCACTCCTGTTTCCA      -19
M~~G~~V~~L~~L~~T~~Q~~R~~T~~L~~L~~S~~L~~V~~L~~A~~L~~L~~F~~P~~      -7

AGCATGGCGAGCATGGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGA      +42
S~~M~~A~~S~~M~~A~~M~~H~~V~~A~~Q~~P~~A~~V~~V~~L~~A~~S~~S~~R~~      +14
                  +1

GGCATCGCTAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTG      +102
G~~I~~A~~S~~F~~V~~C~~E~~Y~~A~~S~~P~~G~~K~~A~~T~~E~~V~~R~~V~~      +34

ACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATG      +162
T~~V~~L~~R~~Q~~A~~D~~S~~Q~~V~~T~~E~~V~~C~~A~~A~~T~~Y~~M~~M~~      +54

GGGAATGAGTTGACCTTCCTAGATGATTCCATCTGCACGGGCACCTCCAGTGGAAATCAA      +222
G~~N~~E~~L~~T~~F~~L~~D~~D~~S~~I~~C~~T~~G~~T~~S~~S~~G~~N~~Q~~      +74

GTGAACCTCACTATCCAAGGACTGAGGGCCATGGACACGGGACTCTACATCTGCAAGGTG      +282
V~~N~~L~~T~~I~~Q~~G~~L~~R~~A~~M~~D~~T~~G~~L~~Y~~I~~C~~K~~V~~      +94

GAGCTCATGTACCCACCGCCATACTACCTGGGCATAGGCAACGGAACCCAGATTTATGTA      +342
E~~L~~M~~Y~~P~~P~~P~~Y~~Y~~L~~G~~I~~G~~N~~G~~T~~Q~~I~~Y~~V~~      +114

ATTGATCCAGAACCGTGCCCAGATTCTGATCAGGAGCCCAAATCTTCTGACAAAACTCAC      +402
I~~D~~P~~E~~P~~C~~P~~D~~S~~D~~Q~~E~~P~~K~~S~~S~~D~~K~~T~~H~~      +134

ACATCCCCACCGTCCCCAGCACCTGAACTCCTGGGTGGATCGTCAGTCTTCCTCTTCCCC      +462
T~~S~~P~~P~~S~~P~~A~~P~~E~~L~~L~~G~~G~~S~~S~~V~~F~~L~~F~~P~~      +154

CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG      +522
P~~K~~P~~K~~D~~T~~L~~M~~I~~S~~R~~T~~P~~E~~V~~T~~C~~V~~V~~V~~      +174

GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG      +582
D~~V~~S~~H~~E~~D~~P~~E~~V~~K~~F~~N~~W~~Y~~V~~D~~G~~V~~E~~V~~      +194

CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGC      +642
H~~N~~A~~K~~T~~K~~P~~R~~E~~E~~Q~~Y~~N~~S~~T~~Y~~R~~V~~V~~S~~      +214

GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC      +702
V~~L~~T~~V~~L~~H~~Q~~D~~W~~L~~N~~G~~K~~E~~Y~~K~~C~~K~~V~~S~~      +234

AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA      +762
N~~K~~A~~L~~P~~A~~P~~I~~E~~K~~T~~I~~S~~K~~A~~K~~G~~Q~~P~~R~~      +254

GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGC      +822
E~~P~~Q~~V~~Y~~T~~L~~P~~P~~S~~R~~D~~E~~L~~T~~K~~N~~Q~~V~~S~~      +274

CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT      +882
L~~T~~C~~L~~V~~K~~G~~F~~Y~~P~~S~~D~~I~~A~~V~~E~~W~~E~~S~~N~~      +294

GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTC      +942
G~~Q~~P~~E~~N~~N~~Y~~K~~T~~T~~P~~P~~V~~L~~D~~S~~D~~G~~S~~F~~      +314

TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCA      +1002
F~~L~~Y~~S~~K~~L~~T~~V~~D~~K~~S~~R~~W~~Q~~Q~~G~~N~~V~~F~~S~~      +334

TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT      +1062
C~~S~~V~~M~~H~~E~~A~~L~~H~~N~~H~~Y~~T~~Q~~K~~S~~L~~S~~L~~S~~      +354

CCGGGTAAATGA
P~~G~~K~~*
```

FIG. 24

FIG. 25A




FIG. 25B





FIG. 25C






FIG. 26




FIG. 27A




FIG. 27B




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 30A




FIG. 30B




FIG. 30C



Inhibition of PHA-induced monkey T cell proliferation
^{3}H thymidine incorporation (cpm)
120000
100000
80000
60000
40000
20000
0
0.01
0.1
1
10
Fusion protein (μg/ml)
L104EA29YIg
CTLA4Ig
Control

FIG. 31



Equilibrium binding to CD86Ig
L104EA29YIg
L104EIg
CTLA4Ig
Response (RU)
900
800
700
600
500
400
300
200
100
0
-100
200
300
400
500
600
700
800
900
1000
Time (sec)

FIG. 32



E-selectin
mean change in baseline (ng/mL)
8
6
4
2
0
-2
-4
-6
-8
Placebo
0.5 mg/kg
2 mg/kg
10 mg/kg
CTLA4Ig
0.5 mg/kg
2 mg/kg
10 mg/kg
LEA29Y
ICAM-1
mean change in baseline (ng/mL)
80
60
40
20
0
-20
-40
-60
-80
-100
Placebo
0.5 mg/kg
2 mg/kg
10 mg/kg
CTLA4Ig
0.5 mg/kg
2 mg/kg
10 mg/kg
LEA29Y

FIG. 33